Strategic Partnerships Vyluma has established collaboration and licensing agreements with Théa, Zhaoke Ophthalmology, and plans expansion in China and Southeast Asia, indicating a proactive channel strategy and potential collaboration opportunities for co-development, licensing, or distribution deals in ophthalmic assets.

Global Expansion Active efforts to commercialize NVK002 in Canada, Mexico, select South American countries, and China/Southeast Asia suggest a readiness to scale into new geographic markets, presenting sales opportunities through regional partnerships, market access, and localized regulatory support.

Product Focus NVK002 appears to be a central asset targeting refractive errors, aligning with ophthalmic manufacturing and specialty drug delivery needs, which could open doors with mid to large ophthalmology distributors, clinics, and hospital networks seeking innovative therapies.

Funding Signals Participation in major healthcare conferences and a revenue range of 1–10 million indicate a growing, investable company with potential for larger contract or license deals, enabling outreach to strategic buyers, CROs, and venture-backed ophthalmology portfolios.

Technology & Reach Utilization of broad tech stack and digital presence shows readiness for scalable operations and data-driven marketing, suggesting opportunities to offer digital health integrations, remote monitoring collaborations, or cloud-enabled regulatory/commercial solutions for ophthalmic products.